Fize Medical
United States · Healthtech · AI
A critical-care monitoring platform that gives clinicians continuous urine-output data and decision support for managing fluid balance and kidney risk.
Continuous kidney data for ICU teams
FIZE kUO measures urine output continuously and provides real-time data to clinicians treating critically ill patients. By replacing intermittent manual measurements with a continuous signal, the system helps care teams see changes in kidney function and fluid status sooner.
From monitoring toward fluid-management guidance
FIZE's platform is designed to support earlier detection of acute kidney injury and more informed fluid-management decisions in intensive care. The company says FIZE kUO has received CE Mark and UKCA certification; its broader Optima software is described as a planned platform for integrating kidney intelligence with therapeutic guidance.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | Undisclosed | Asahi Kasei Medical — LeadRapha Capital Management — Lead |